Drug Discovery World

SEPTEMBER 6, 2022

As is always the case with pharmaceuticals, the industry’s capabilities to manufacture and produce these potentially life-saving therapies will be of concern. . The Cell and Gene Therapy Skills Demand Survey Report predicts a demand of 10,000 bioprocessing jobs in the UK by 2026. . Manufacturing . Workforce .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

The Pharma Data

DECEMBER 12, 2020

12, 2020– AstraZeneca and Alexion Pharmaceuticals, Inc. AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. 2 EvaluatePharma, World Preview 2020, Outlook to 2026.

Regulations 75

Regulations International Disease Small Molecule 75

Agency IQ

JULY 26, 2024

in equipment) for products that are more complex or aren’t as well-characterized, such as antibody drug conjugates or recombinant DNA products, will be considered higher risk than they would if the change was made to the production of standard, small molecule products. Any CMC changes (e.g., Comments are due September 23, 2024.

Biosimilars 40

Biosimilars Science FDA Licensing 40

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Pfizer announced several key advances in its efforts to protect humankind from the COVID-19 pandemic and prepare the pharmaceutical industry to better respond to future global health crises.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52